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Test-negative designBackground: The test-negative design (TND), an epidemiologic method currently used to measure rota-
virus vaccine (RV) effectiveness, compares the vaccination status of rotavirus-positive cases and
rotavirus-negative controls meeting a pre-defined case definition for acute gastroenteritis. Despite the
use of this study design in low-income settings, the TND has not been evaluated to measure rotavirus
vaccine effectiveness.
Methods: This study builds upon prior methods to evaluate the use of the TND for influenza vaccine using
a randomized controlled clinical trial database. Test-negative vaccine effectiveness (VE-TND) estimates
were derived from three large randomized placebo-controlled trials (RCTs) of monovalent (RV1) and
pentavalent (RV5) rotavirus vaccines in sub-Saharan Africa and Asia. Derived VE-TND estimates were
compared to the original RCT vaccine efficacy estimates (VE-RCTs). The core assumption of the TND
(i.e., rotavirus vaccine has no effect on rotavirus-negative diarrhea) was also assessed.
Results: TND vaccine effectiveness estimates were nearly equivalent to original RCT vaccine efficacy
estimates. Neither RV had a substantial effect on rotavirus-negative diarrhea.
Conclusions: This study supports the TND as an appropriate epidemiologic study design to measure
rotavirus vaccine effectiveness in low-income settings.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Globally, an estimated 200,000 deaths due to rotavirus diarrhea
occur annually in children <5 years old, with a majority of the
burden in low-income settings [1]. Starting in 2006, two rotavirus
vaccines have been introduced worldwide; GlaxoSmithKline’s
live-attenuated human monovalent vaccine (Rotarix [RV1]) and
Merck’s live-attenuated pentavalent human-bovine reassortant
vaccine (RotaTeq [RV5]). Large multi-site randomized controlled
trials (RCTs) of RV1 and RV5 in low-income settings have
demonstrated moderate vaccine efficacy against severe rotavirus
gastroenteritis in the first year of life (VE: 51–64%) [2–6]. As of
May 1, 2016, rotavirus vaccines have been introduced nationallyin 38 Gavi-eligible countries. However, many high-burden
countries have not introduced the vaccine and approximately
70% of the world’s infants still do not have access to rotavirus vac-
cine [7]. Accurate post-introduction monitoring of effectiveness
measures is important as results can influence the adoption of
rotavirus vaccines in new areas and sustain support in countries
where vaccines have been introduced.
Case-control studies are an efficient means to monitor effective-
ness and provide confidence in vaccine performance. In low-
income settings, identifying community controls, either using a
demographic surveillance system or sampling the community in-
person, can be impractical and expensive. Hospital controls can
be used to minimize bias due to healthcare seeking behavior. How-
ever, for rotavirus vaccine studies, careful consideration must be
made to use hospital controls without diarrhea or any illness asso-
ciated with vaccine-preventable diseases. The test-negative design
(TND) can theoretically overcome the limitations of both
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healthcare seeking behavior [8]. TND rotavirus vaccine studies
enroll cases presenting to a medical facility for acute gastroenteri-
tis and are rotavirus-positive using standard laboratory methods.
Controls include those presenting to a medical facility with the
same pre-defined case definition of acute gastroenteritis, but are
rotavirus-negative. Both traditional case-control and test-
negative study designs require rotavirus testing on infants present-
ing to the clinic with diarrhea to identify cases. The TND is efficient
and cost-effective in that those testing-negative for rotavirus serve
as the control group, instead of being excluded from the study.
The TND has been used extensively to measure annual influenza
vaccine effectiveness [8,9]. Simulation experiments have validated
the test-negative design for influenza vaccine under specific core
assumptions: (1) vaccine has no effect on the incidence of non-
influenza pathogens, (2) a highly sensitive and specific laboratory
test is used for pathogen detection, and (3) other sources of bias
present in observational studies are minimized [8–14]. De Serres
et al. validated the TND for influenza vaccine utilizing RCT data-
bases to verify the accuracy and precision of TND estimates and
to test the assumption that the vaccines had no effect on non-
influenza respiratory illness [15]. RCTs are appropriate to validate
this design due to limited selection bias and confounding as a result
of randomization and blinding, the use of standardized laboratory
testing, and enhanced surveillance. Derived test-negative vaccine
effectiveness estimates for influenza vaccines were almost identical
to the original RCT vaccine efficacy estimates. Importantly, the vac-
cine coverage in the test-negative controls represented the vaccine
coverage in the underlying study population, upholding the key
assumption that the vaccine had no effect on non-influenza illness.
Together, these results indicated the TNDwas a valid epidemiologic
study design to measure influenza vaccine effectiveness [15].
The TND is being increasingly used to estimate rotavirus vac-
cine effectiveness in middle- and low-income settings due to its
low cost and feasibility,[16–26] but little has been done to assess
this epidemiologic study design in the context of rotavirus vaccine
effectiveness in low-income settings. In the present analysis, RCT
databases for RV1 and RV5 in sub-Saharan Africa and Asia were
used to evaluate the TND.2. Methods
2.1. Participants and study design
Databases from three multi-center, double-blind, individual-
randomized, placebo-controlled, trials of rotavirus vaccines inTable 1
Summary of rotavirus vaccine clinical trials in low-income settings.
Vaccine Dosing schedule Surveillance type Study site Age dur
follow-
Rotarix
(RV1)
6, 10, 14 weeks
or 10,14 weeks
Active: Scheduled weekly
home visits and clinic visits
South
Africa <1 Yea
Malawi
South
Africa 1–<2 Ye
Malawi
RotaTeq
(RV5)
6, 10, 14 weeks Passive: clinic visits
Ghana
<2 YeaKenya
Mali
RotaTeq
(RV5) 6, 10, 14 weeks Passive: clinic visits
Bangladesh
<2 YeaVietnam
* Vaccine efficacy was estimated separately in South Africa and Malawi for the seconsub-Saharan Africa and Asia were used [2–6]. Table 1 summarizes
location, vaccine schedule, per-protocol population size, and
surveillance type of the three RCTs.
2.1.1. RV1
This trial was conducted in South Africa and Malawi. Between
2005 and 2007, 4939 healthy infants aged 5–10 weeks were ran-
domly assigned to one of three groups in a 1:1:1 ratio: two doses
of RV1, three doses of RV1, or three doses of placebo. Gastroenteri-
tis was defined as three or more loose or watery stools within 24 h.
Clinical characteristics of each diarrheal episode were documented
to define severity based on the Vesikari score [27]. Stool samples
were tested for rotavirus using enzyme-linked immunosorbent
assay (ELISA). The primary outcome was at least one episode of
severe rotavirus gastroenteritis (Vesikari score P11). Vaccine effi-
cacy was estimated during the period from two weeks after the last
dose until the first year of age. Within each study site, a sub-cohort
was followed into the second year of life. The mean age at the end
of follow-up was 14 months and 19 months for South Africa and
Malawi, respectively.
2.1.2. RV5
Two trials of RV5 were conducted in sub-Saharan Africa and
Asia between 2007 and 2009. Both trials were conducted under
similar protocols; however, the trials were powered and imple-
mented separately. In sub-Saharan Africa, 5468 healthy infants
were enrolled in Ghana, Kenya, and Mali. In Asia, 2036 healthy
infants were enrolled in Bangladesh and Vietnam. Infants aged
4–12 weeks were randomly assigned to one of two groups in a
1:1 ratio: three doses of RV5 or three doses of placebo. As in the
RV1 trial, severe rotavirus gastroenteritis was defined based on a
positive ELISA laboratory result and Vesikari score P11. Vaccine
efficacy was estimated during the period from two weeks after
the last dose until the end of follow-up (March 31, 2009). The mean
age at the end of follow-up was 20 months and 19 months for sub-
Saharan Africa and Asia, respectively.
For the purposes of this analysis, participants with an episode of
severe diarrhea meeting the pre-defined case definition and with
an available ELISA test result were categorized as a case if the test
was positive for rotavirus or a control if the test was negative for
rotavirus. Continuous diarrheal surveillance during the study per-
iod allowed for the identification of multiple diarrheal episodes
for each participant. A participant was defined as a case if at least
one severe rotavirus-positive diarrheal episode occurred during
follow-up. A participant was defined as a control if at least one sev-
ere rotavirus-negative diarrheal episode occurred during follow-up
and the participant had no severe rotavirus-positive episodes.ing
up
Primary per-protocol
population (Vaccine/
Placebo)
Country specific per-protocol
population (Vaccine/Placebo)
Reference
rs 2974/1443
1944/960
[2]
1030/483
ars *
686/332 [3]
814/380 [4]
rs 2404/2385
940/930
[5]573/577
891/878
rs 995/988
557/561
[6]438/427
d year of this study.
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Logistic regression was used to estimate the relative odds and
associated 95% confidence intervals (CI) of severe rotavirus-
positive diarrhea compared to severe rotavirus-negative diarrhea
by vaccine and placebo status. TND vaccine effectiveness (VE-
TND) was defined as (1  Odds Ratio)  100. The relative percent
difference between VE-TND and the original RCT vaccine efficacy
(VE-RCT) was calculated. To estimate the influence of vaccine on
rotavirus-negative diarrhea (VE-NEG), the relative risk of severe
rotavirus-negative diarrhea in the vaccine group compared to the
placebo group with exact 95% CIs were calculated. VE-NEG was
defined as (1  Relative Risk)  100.
The analysis was based on the per-protocol participant popula-
tions. The primary analysis of each RCT, combining country-level
estimates, was replicated. Additionally, analyses were stratified
by country. The RV1 trial was powered to estimate vaccine efficacy
for two and three doses separately, therefore analyses were repli-
cated by these dosing combinations. Each trial included diarrheal
surveillance on all or a subset of participants into the second year
of life. Analyses were conducted for the complete follow-up period
(<2 years of age) and separately for diarrheal episodes identified
during the first (<1 years of age) and second (1–<2 years of age)
years of life. Analyses conducted within the second year of life
did not exclude participants with diarrheal episodes during the
first year of life. For the RV1 trial, different methods of enrollment
into the second year were used for each country; therefore, analy-
ses for the second year of life and complete follow-up were con-
ducted separately for South Africa and Malawi.
In practice, differences in age and time at presentation between
cases and test-negative controls are controlled by matching or by
adjusting analyses by both month and year of birth and month
and year of presentation. Additional analyses were restricted by
rotavirus season in Ghana and Mali due to the observed seasonality
in these regions. To replicate the primary efficacy results of the RV5
trial, diarrheal episodes identified during the rotavirus seasons in
Ghana and Mali were combined with the year-round diarrheal epi-
sodes in Kenya to estimate country-combined estimates.
Analyses were completed using STATA version 14 (Stata Corpo-
ration, College Station, TX, USA) and the SAS Clinical Trial Data
Transparency software system through the online GSK portal
(SAS Institute Inc., Cary, NC, USA).
3. Results
Table 2 shows the derived test-negative vaccine effectiveness
estimates (VE-TND), the original RCT vaccine efficacy estimates
(VE-RCT), and the relative percent difference between these esti-
mates in the RV1 trial. During the first year of life (<1 years of
age), the country-combined and country-specific efficacy and
effectiveness estimates for all doses were similar (two or three
doses combined in South Africa and Malawi: VE-TND: 58.2% [95%
CI: 35.5–72.9]; VE-RCT: 61.2% [95%CI: 44.0–73.2]; 4.9% relative
difference). The sub-cohort in South Africa followed over two rota-
virus seasons yielded a low sample of rotavirus-positive cases
resulting in less robust estimates during both the second year of
life (1<2 years of age) and using complete follow-up (<2 years
of age). The sub-cohort in Malawi followed over two rotavirus sea-
sons resulted in VE-TND and VE-RCT estimates which were not
meaningfully different during any periods of follow-up.
VE-TND and VE-RCT estimates for the RV5 trial in sub-Saharan
Africa are shown in Table 3. Using diarrheal episodes identified in
the first year of life (<1 years of age), the VE-TND and the VE-RCT
are almost identical, particularly in the country-combined estimate
(VE-TND: 66.9% [95%CI: 42.7–80.9]; VE-RCT: 64.2% [95%CI:
40.2–79.4]; 4.2% relative difference). In the second year of life(1–<2 years of age) the VE-TND was greater than the VE-RCT for
both country-combined and country-specific estimates in the sec-
ond year (combined African study sites: VE-TND: 39.4% [95%CI:
5.0–61.4]; VE-RCT: 19.6% [95%CI: 15.7–44.4]; 101.0% relative dif-
ference). Using complete follow-up (<2 years of age), the VE-TND
was moderately greater than the VE-RCT in all study settings (com-
bined African study sites: VE-TND: 51.9% [95%CI: 32.1–65.9]; VE-
RCT: 39.3% [95%CI: 19.1–54.7]; 32.1% relative difference).
In this trial, the rotavirus season in Ghana occurred between
January and March. After restricting the analysis to diarrheal epi-
sodes during this time period (Table 3), there was no meaningful
difference between the VE-TND and VE-RCT estimates (VE-TND:
56.1% [95%CI: 8.3–82.2]; VE-RCT: 55.5% [95%CI: 28.0–73.1]; 1%
relative difference). Similarly, after restricting the analysis in Mali
to the rotavirus season (October through February), the relative
difference between VE-TND and VE-RCT estimates decreased (VE-
TND: 9.4% [95%CI: 73.3–52.7]; VE-RCT: 17.6% [95%CI: 22.9–
45.0]; 46.6% relative difference). In both rotavirus-season
restricted analyses, sample size decreased substantially. Combin-
ing diarrheal episodes in Ghana and Mali during their respective
rotavirus seasons with year-round diarrheal episodes in Kenya,
resulted in a 5.3% relative difference between country-combined
VE-TND and VE-RCT estimates.
Table 4 shows the VE-TND and VE-RCT estimates for the RV5
trial in Asia. VE-TND and VE-RCT estimates were not meaningfully
different in country-combined analyses or during any periods of
follow-up (combined Asian study sites using complete follow-up
(<2 years of age): VE-TND: 49.8% [95%CI: 14.6–70.5]; VE-RCT:
48.3% [95%CI: 22.3–66.1]; 3.1% relative difference).
Fig. 1 summarizes the VE-TND and VE-RCT estimates and over-
lapping 95% CIs for all RCTs during the first year of life and using
the complete follow-up (<2 years of age).
Table 5 shows both RV1 and RV5 vaccine efficacy against severe
rotavirus-negative diarrhea (VE-NEG). In the RV1 trial, the magni-
tude of VE-NEGwas greatest in South Africa during the second year
of follow-up with three doses of vaccine (54.0% [95%CI: 7.1–77.2]),
while all other age and dose combinations had a low VE-NEG. In
the RV5 trial in sub-Saharan Africa, the magnitude of the VE-NEG
was greatest in Ghana during the second year of life (1–<2 years
of age: 50.5 [95%CI: 170.9–14.9]), and using complete follow-
up (<2 years of age: 49.1 [95%CI: 117.9 to 2.7]), compared to
other settings. The country-combined VE-NEG was statistically sig-
nificant using complete follow-up. After restricting the analysis to
the rotavirus season using complete follow-up, the VE-NEG
decreased in all RV5 settings with no statistically significant esti-
mates. In the RV5 trial in Asia, the magnitudes of the country-
combined VE-NEG estimates were low (<20%) during all follow-
up periods. Due to the low magnitude of each VE-NEG, the ratio
of vaccine: placebo test-negative controls replicated the 2:1 or
1:1 randomized vaccine coverage of the underlying study popula-
tion in most study settings.4. Discussion
Overall, the results from the TND analysis for RV1 and RV5 in
sub-Saharan Africa and Asia were similar to primary efficacy
results. The heterogeneity of vaccine effectiveness estimates
between countries was also observed. In countries with a marked
rotavirus season, estimates were not meaningfully different after
restricting analyses to these time periods. We also demonstrated
that RV1 and RV5 had no effect on severe rotavirus-negative diar-
rhea, a key assumption of the TND.
VE-TND during the first year of life was comparable to VE-RCT
for all three trials. The control group accurately represented the
vaccine coverage of the underlying study population. For example,
Table 2
RV1 test-negative design results.
Study Site Age (Years) Doses Cases* Controls* VE-TND (95%CI) VE-RCT (95%CI) % Relative difference**
South Africa and Malawi <1
2 or 3 doses 56/70 174/91 58.2 (35.5–72.9) 61.2 (44.0–73.2) 4.9
2 doses 30/70 93/91 58.1 (29.7–75.0) 58.7 (35.7–74.0) 1.0
3 doses 26/70 81/91 58.3 (28.3–75.7) 63.7 (42.4–77.8) 8.5
South Africa <1
2 or 3 doses 15/32 46/25 74.5 (44.3–88.4) 76.9 (56.0–88.4) 3.1
2 doses 9/32 24/25 70.7 (25.9–88.4) 72.2 (40.4–88.3) 2.1
3 doses 6/32 22/25 78.7 (39.5–92.5) 81.5 (55.1–93.7) 3.4
Malawi <1
2 or 3 doses 41/38 128/66 44.4 (5.3–67.3) 49.4 (19.2–68.3) 10.1
2 doses 21/38 69/66 47.1 (0.7–71.9) 49.2 (11.1–71.7) 4.3
3 doses 20/38 59/66 41.1 (12.3–69.1) 49.7 (11.3–72.7) 17.3
South Africa 1–<2
2 or 3 doses 5/4 32/23 10.2 (271.6–78.3) 40.0 (204.0–87.0) 74.5
2 doses 4/4 21/23 9.5 (394.2–75.7) 3.0 (43.0–82.0) 416.7
3 doses 1/4 11/23 47.4 (424.6–94.8) 76.0 (143.0–100.0) 37.6
Malawi 1–<2
2 or 3 doses 30/17 89/45 10.8 (78.7–55.5) 17.6 (59.2–56.0) 38.6
2 doses 18/17 44/45 8.3 (136–50.5) 2.6 (101.2–52.6) 419.2
3 doses 12/17 45/45 29.4 (64.6–68.7) 33.1 (48.6–70.9) 11.2
South Africa <2
2 or 3 doses 11/13 58/32 53.3 (16.2–81.2) 59.0 (1.0–83.0) 9.7
2 doses 9/13 38/32 41.7 (54.0–77.9) 32.0 (71.0–75.0) 30.3
3 doses 2/13 20/32 75.4 (20.7–95.0) 85.0 (35.0–98.0) 11.3
Malawi <2
2 or 3 doses 69/53 183/90 36.0 (0.8–58.7) 38.1 (9.8–57.3) 5.5
2 doses 38/53 96/90 32.8 (11.5–59.5) 34.0 (2.0–57.7) 3.5
3 doses 31/53 87/90 39.5 (3.0–64.5) 42.3 (8.8–64.0) 6.6
Cases: severe (VesikariP 11) rotavirus-positive diarrhea.
Controls: severe rotavirus-negative diarrhea.
VE-TND: Vaccine effectiveness against severe rotavirus diarrhea using the test-negative design.
VE-RCT: Vaccine efficacy against severe rotavirus diarrhea-original randomized control trial estimates.
* No. Vaccine/No. Placebo.
** VE-TND compared to VE-RCT.
Table 3
RV5 test-negative design results in sub-Saharan Africa.
Study Site Age (Years) Cases* Controls* VE-TND (95%CI) VE-RCT (95%CI) % Relative difference**
African study sites
<1
23/61 115/101 66.9 (42.7–80.9) 64.2 (40.2–79.4) 4.2
Ghana 16/42 44/36 68.8 (35.6–84.9) 65.0 (35.5–81.9) 5.8
Kenya 2/14 23/16 90.1 (50.1–98.0) 83.4 (25.5–m98.2) 8.0
Mali 5/5 48/49 2.1 (275.3–72.2) 1.0 (431.7–81.6) 310.0
African study sites
1–<2
57/71 110/83 39.4 (5.0–61.4) 19.6 (15.7–44.4) 101.0
Ghana 11/15 33/22 51.1 (26.0–81.0) 29.4 (64.6–70.7) 73.8
Kenya 3/2 8/11 106.3 (1435.7–72.3) 54.7 (1752.7–82.3) 94.3
Mali 43/54 69/50 42.3 (0.9–66.4) 19.2 (23.1–47.3) 120.3
African study sites
<2
80/132 208/165 51.9 (32.1–65.9) 39.3 (19.1–54.7) 32.1
Ghana 27/57 74/50 68.0 (42.7–82.1) 55.5 (28.0–73.1) 22.5
Kenya 5/16 27/25 71.1 (9.3–90.8) 63.9 (5.9–89.8) 11.3
Mali 48/59 107/90 31.6 (9.8–57.4) 17.6 (22.9–45.0) 79.5
Restricted to Rotavirus Season
African study sitesa
<2
69/123 68/71 41.4 (6.4–63.3) 39.3 (19.1–54.7) 5.3
Ghanaa 22/54 13/14 56.1 (8.3–82.2) 55.5 (28.0–73.1) 1.1
Kenya 5/16 27/25 71.1 (9.3–90.8) 63.9 (5.9–89.8) 11.3
Malia 42/53 28/32 9.4 (73.3–52.7) 17.6 (22.9–45.0) 46.6
Cases: severe (VesikariP 11) rotavirus-positive diarrhea.
Controls: severe rotavirus-negative diarrhea.
VE-TND: Vaccine effectiveness against severe rotavirus diarrhea using the test-negative design.
VE-RCT: Vaccine efficacy against severe rotavirus diarrhea-original randomized control trial estimates.
* No. Vaccine/No. Placebo.
** VE-TND compared to VE-RCT.
a Cases/controls restricted to rotavirus season in Ghana (January-March) and Mali (October-February), but year-round in Kenya.
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cebo controls is nearly 1:1 (93:91), the randomized vaccine: pla-
cebo ratio. In all trials, VE-TND estimates during the second year
of life were largely limited by the low number of diarrheal episodes
and rotavirus-positive cases identified. Primary VE-RCTs for the
second year of life were not statistically significant and this was
replicated in the VE-TND results. The sustained effect of rotavirus
vaccine during the second year of life remains unclear [3,28].In the analysis using complete follow-up (<2 years of age), the
VE-TND was similar to the VE-RCT in RV1 and RV5-Asia. Differ-
ences between the estimates were demonstrated in the RV5 trial
in sub-Saharan Africa for country-combined and country-specific
estimates. Ghana and Mali have distinct rotavirus seasons. Analy-
ses were restricted to the rotavirus season in order to obtain
time-matched controls. This strategy better emulates the practice
of incidence density sampling and provides results that are closer
Table 4
RV5 test-negative design results in Asia.
study site Age (Years) Cases* Controls* VE-TND (95%CI) VE-RCT (95%CI) % Relative difference**
Asian study sites
<1
19/38 36/40 44.4 (13.2–72.7) 51.0 (12.8–73.3) 12.9
Bangladesh 17/31 31/38 32.8 (43.5–68.5) 45.7 (1.2–71.8) 28.2
Vietnam 2/7 5/2 88.6 (10.8–98.8) 72.3 (45.2–97.2) 22.5
Asian study sites
1–<2
19/34 27/23 52.4 (4.9–78.4) 45.5 (1.2–70.7) 15.2
Bangladesh 16/25 23/18 42.3 (0.9–66.4) 39.3 (18.3–69.7) 7.6
Vietnam 3/9 4/5 58.3 (166.0–93.5) 64.6 (47.7–93.9) 9.8
Asian study sites
<2
38/72 62/59 49.8 (14.6–70.5) 48.3 (22.3–66.1) 3.1
Bangladesh 33/56 53/52 42.2 (2.8–67.5) 42.7 (10.4–63.9) 1.2
Vietnam 5/16 9/7 75.7 (0.6–94.1) 63.9 (7.6–90.9) 18.5
Cases: severe (VesikariP 11) rotavirus-positive diarrhea.
Controls: severe rotavirus-negative diarrhea.
VE-TND: Vaccine effectiveness against severe rotavirus diarrhea using the test-negative design.
VE-RCT: Vaccine efficacy against severe rotavirus diarrhea-original randomized control trial estimates.
* No. Vaccine/No. Placebo.
** VE-TND compared to VE-RCT.
*VE-TND is restricted to rotavirus season in Ghana (January -March) 
RV1-Africa: <1 Year, VE-TND
RV1-Africa: <1 Year, VE-RCT
RV5-Africa: <1 Year, VE-TND
RV5-Africa: <1 Year, VE-RCT
RV5-Africa: <2 Years, VE-TND
*RV5-Africa: <2 Years, VE-TND
RV5-Africa: <2 Years, VE-RCT
RV5-Asia: <1 Year, VE-TND
RV5-Asia: <1 Year, VE-RCT
RV5-Asia: <2 Years, VE-TND
RV5-Asia: <2 Years, VE-RCT
-15 0 15 30 45 60 75 90
Vaccine Efficacy
and Mali (October-February), but year-round in Kenya 
Fig. 1. VE-TND and VE-RCT estimates and 95% confidence intervals for each rotavirus vaccine RCT.
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an RCT. These results support the importance of temporally
matched controls or accounting for timing of birth and case pre-
sentation in the TND to obtain accurate vaccine effectiveness
estimates.
Generally, less robust VE-TND and VE-RCT estimates in Mali are
in part due to changes in surveillance after the first year of the
study, which initially missed most of the rotavirus season and
yielded a low number of rotavirus cases. Surveillance and commu-
nity engagement increased during the second year of the trial to
increase case capture [5]. Notably, during the first year the ratio
of vaccinated controls to placebo controls is almost exactly 1:1
(48:49), indicating the surveillance appropriately identified the
underlying vaccine coverage in test-negative controls during this
time.
Further evidence of the accuracy of the test-negative control
group is demonstrated in rotavirus vaccine case-control studies
using multiple control groups in sub-Saharan Africa and Latin
America [17,19,20,23,29]. In Malawi, RV1 effectiveness for severe
rotavirus-positive diarrhea during the first year of life was similar
using test-negative controls and community controls (VE-TND:
68%, VE-Community controls: 68%) [17]. In South Africa, RV1 effec-
tiveness for hospital admission with rotavirus-positive diarrhea in
children <2 years old was comparable using test-negative controls
and hospitalized controls (VE-TND: 57%, VE-Hospital controls:63%) [20]. In Bolivia, RV1 effectiveness for severe rotavirus-
positive diarrhea during the first year of life was moderately differ-
ent using test-negative controls and hospitalized controls (VE-
TND: 66%, VE-Hospital controls: 78%) [29]. In Nicaragua, RV5 effec-
tiveness for severe rotavirus-positive diarrhea during the first year
of life was slightly different using test-negative controls and a
combined group of hospitalized and community controls (VE-
TND: 70%, VE-Hospital/Community controls: 83%). In children
>1 years old, the difference in estimates was more substantial
(VE-TND: 33%, VE-Hospital/Community controls:70%) [19].
Authors suggest the combined control group differed from the
test-negative and test-positive participants, likely due to health-
care seeking behaviors. In Guatemala RV1 and RV5 effectiveness
against a rotavirus-positive diarrheal episode resulting in a hospi-
tal visit was moderately different using test-negative controls and
hospitalized controls (VE-TND: 52%, VE-Hospital controls: 74%)
[23]. All studies observed vaccine effectiveness results similar to
efficacy estimates of RCTs conducted in Latin America.
Importantly, while the TND can be valuable, this study design is
susceptible to biases present in all observational studies including
selection bias, confounding, and misclassification of vaccine and
rotavirus status [14]. In these RCTs we are highly confident of accu-
rate vaccine ascertainment, but this can be problematic in the field
with missing documentation, unreliable parental recall, and the
added complexities of multiple doses [30]. Additionally, the
Table 5
RV1 and RV5 vaccine efficacy against severe rotavirus-negative diarrhea results.
Vaccine Study site Age (Years) Doses VE-NEG (95%CI)
RV1
South Africa and Malawi <1
2 or 3 doses 7.2 (18.6–27.4)
2 doses 1.4 (30.4–25.5)
3 doses 13.1 (16.2–35.0)
South Africa <1
2 or 3 doses 9.1 (47.0–43.8)
2 doses 5.1 (65.0–45.4)
3 doses 13.2 (52.9–50.7)
Malawi <1
2 or 3 doses 9.1 (19.9–31.0)
2 doses 3.8 (31.7–29.7)
3 doses 14.5 (18.7–38.4)
South Africa 1–e<2
2 or 3 doses 32.7 (13.2–60.0)
2 doses 11.1 (57.5–49.8)
3 doses 54.0 (7.1–77.2)
Malawi 1–<2
2 or 3 doses 7.7 (29.4–34.1)
2 doses 10.0 (33.1–39.2)
3 doses 5.2 (39.8–35.8)
South Africa <2
2 or 3 doses 12.3 (32.9–42.1)
2 doses 15.9 (81.8–26.1)
3 doses 40.0 (3.2–65.1)
Malawi <2
2 or 3 doses 4.7 (19.8–24.1)
2 doses 1.9 (27.2–24.3)
3 doses 7.5 (20.7–29.2)
RV5
African study sites
<1 3 doses
13.3 (49.6–14.0)
Ghana 21.4 (94.1–23.6)
Kenya 46.4 (196.6–25.9)
Mali 3.7 (46.5–36.7)
African study sites
1–<2 3 dosesm
33.1 (79.1–0.8)
Ghana 50.5 (170.9–14.9)
Kenya 27.3 (98.5–74.6)
Mali 38.9 (104.1–4.9)
African study sites
<2 3 doses
26.5 (56.1 to 2.6)
Ghana 49.1 (117.9 to 2.7)
Kenya 9.2 (96.1–39.0)
Mali 18.4 (58.5–11.4)
RV5: Restricted to Rotavirus Seasona
African study sites
<2 3 doses
5.1 (34.3–32.9)
Ghana 8.1 (110.7–60.2)
Kenya 9.2 (96.1–39.0)
Mali 13.9 (47.5–50.1)
RV5
Asian Study Sites
<1 3 doses
10.8 (43.6–44.7)
Bangladesh 18.5 (34.6–50.9)
Vietnam 145.3 (2375.8–59.8)
Asian Study Sites
1–<2 3 doses
17.2 (113.9–35.3)
Bangladesh 38.9 (104.1–4.9)
Vietnam 22.0 (262.4–84.5)
Asian Study Sites
<2 3 doses
4.8 (52.3–27.8)
Bangladesh 2.8 (53.7–31.2)
Vietnam 26.0 (298.3–58.2)
a Cases/controls restricted to rotavirus season in Ghana (January-March) and Mali (October-February), but year-round in Kenya.
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gen is especially important when using the TND. A test with low
specificity influences results more substantially than a test with
low sensitivity [10]. All RCTs and case-control studies used ELISA
for rotavirus detection. While RT-PCR is the gold standard, ELISA
has high sensitivity (75–82%) and specificity (100%) to identify
rotavirus [31]. A simulation study comparing true and estimated
TND vaccine effectiveness results based on varying rotavirus test
characteristics and attack rates demonstrated minimal bias with
the currently used ELISA [32].
This analysis evaluated the use of the TND to estimate rotavirus
vaccine effectiveness in low-income settings. Three separate
rotavirus vaccine trials, testing two vaccines in seven countries,
showed TND vaccine effectiveness estimates were nearly identical
to the primary efficacy estimates of the original RCTs. The key
assumption of the TND, the vaccine has no impact on rotavirus-negative diarrhea, was also upheld. This study supports the test-
negative design as an appropriate method to measure rotavirus
vaccine effectiveness in low-income settings.Funding
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